http://www.advfn.com/nasdaq/rss.asp?symbol=ISIS Isis Pharmaceuticals Company Newsfeed en Mon, 08 Apr 2013 09:59:37 EDT Mon, 08 Apr 2013 09:59:37 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ISIS&article=57067139&headline=isis-pharmaceuticals-roche-to-collaborate-on-huntingtons-disease http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ISIS&article=57067139&headline=isis-pharmaceuticals-roche-to-collaborate-on-huntingtons-disease <div class='newsbody'><pre> By Melodie Warner </pre> <p> Isis Pharmaceuticals Inc. (ISIS) and Roche Holding AG (RHHBY, RO.EB, ROG.VX) have formed an alliance to develop Huntington's disease treatments using Isis's antisense oligonucleotide technology. </p> <p> Huntington's disease is an inherited genetic... Mon, 08 Apr 2013 09:59:37 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ISIS&article=56062984&headline=u-s-hot-stock-futures-hot-stocks-to-watch http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ISIS&article=56062984&headline=u-s-hot-stock-futures-hot-stocks-to-watch <div class='newsbody'><p> Among the companies with shares expected to actively trade in Wednesday's session are Amazon.com Inc. (AMZN), Copano Energy LLC (CPNO) and Chesapeake Energy Corp. (CHK). </p> <p> Amazon.com posted a 45% drop in earnings in the fourth quarter, but some other measures of the online... Wed, 30 Jan 2013 09:17:18 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ISIS&article=56052368&headline=fda-approves-sanofis-kynamro-to-treat-rare-cholesterol-disorder http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ISIS&article=56052368&headline=fda-approves-sanofis-kynamro-to-treat-rare-cholesterol-disorder <div class='newsbody'><pre> By Jennifer Corbett Dooren </pre> <p> WASHINGTON--The U.S. Food and Drug Administration Tuesday approved a drug called Kynamro that will be marketed by marketed by Sanofi's (SNY, SNY.FR) Genzyme unit to treat a rare form of a disease that causes very high cholesterol. </p> <p>... Tue, 29 Jan 2013 19:10:12 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ISIS&article=55466796&headline=sanofis-genzyme-eu-regulator-issues-negative-opinion-for-kynamro http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ISIS&article=55466796&headline=sanofis-genzyme-eu-regulator-issues-negative-opinion-for-kynamro <div class='newsbody'><p> U.S. pharmaceutical company Genzyme, a unit of French group Sanofi SA (SAN.FR), and Isis Pharmaceuticals Inc. (ISIS) Friday said the Committee for Medicinal Products for Human Use of the European Medicines Agency, the body that authorizes drugs in the European Union, issued... Fri, 14 Dec 2012 08:32:34 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ISIS&article=55466668&headline=isis-genzyme-chmp-issues-negative-opinion-on-cholesterol-drug http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ISIS&article=55466668&headline=isis-genzyme-chmp-issues-negative-opinion-on-cholesterol-drug <div class='newsbody'><pre> By Ben Fox Rubin </pre> <p> Isis Pharmaceuticals Inc. (ISIS) and Genzyme, a Sanofi (SNY, SAN.FR) business, said the Committee for Medicinal Products for Human Use adopted a negative opinion for its marketing authorization of the cholesterol drug Kynamro, a setback for the... Fri, 14 Dec 2012 08:28:19 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ISIS&article=55447971&headline=isiss-transthyretin-amyloidosis-treatment-gets-fast-track-fda http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ISIS&article=55447971&headline=isiss-transthyretin-amyloidosis-treatment-gets-fast-track-fda <div class='newsbody'><pre> By Saabira Chaudhuri </pre> <p> Isis Pharmaceuticals Inc. (ISIS) said it has received fast-track designation from the U.S. Food and Drug Administration for the treatment for familial amyloid polyneuropathy, a type of genetic disease. </p> <p> ISIS-TTR is an antisense drug... Thu, 13 Dec 2012 09:24:27 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ISIS&article=55404738&headline=isis-strikes-cancer-targets-agreement-worth-31-million-with http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ISIS&article=55404738&headline=isis-strikes-cancer-targets-agreement-worth-31-million-with <div class='newsbody'><pre> By Saabira Chaudhuri </pre> <p> Isis Pharmaceuticals Inc. (ISIS) has struck a deal with AstraZeneca PLC (AZN, AZN.LN) to develop novel generation antisense therapeutics against five cancer targets that includes a license to develop ISIS-STAT3, a drug Isis is currently evaluating... Tue, 11 Dec 2012 07:52:51 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ISIS&article=54600788&headline=fda-panel-supports-genzyme-isis-drug-mipomersen-on-9-6-vote http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ISIS&article=54600788&headline=fda-panel-supports-genzyme-isis-drug-mipomersen-on-9-6-vote <div class='newsbody'><pre> By Jennifer Corbett Dooren </pre> <p> WASHINGTON--A federal advisory panel voted to support the use of mipomersen, a drug that would be marketed by Sanofi's (SNY, SNY.FR) Genzyme unit to treat a rare form of a disease that causes very high cholesterol. </p> <p> But many panel... Thu, 18 Oct 2012 15:56:36 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ISIS&article=52944369&headline=biogen-idec-isis-pharma-in-pact-for-drug-to-treat-steinart-disease http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ISIS&article=52944369&headline=biogen-idec-isis-pharma-in-pact-for-drug-to-treat-steinart-disease <div class='newsbody'><pre> By Chelsea Stevenson </pre> <p> Biogen Idec Inc. (BIIB) and Isis Pharmaceuticals Inc. (ISIS) entered into an agreement to develop and commercialize an antisense drug to treat Steinert disease, a deal that could see Isis receive more than $271 million. </p> <p> Steinert disease... Fri, 29 Jun 2012 09:18:18 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ISIS&article=50613007&headline=biogen-isis-enter-collaboration-on-spinal-atrophy-treatment http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ISIS&article=50613007&headline=biogen-isis-enter-collaboration-on-spinal-atrophy-treatment <div class='newsbody'><p> DOW JONES NEWSWIRES </p> <p> Isis Pharmaceuticals, Inc. (ISIS) entered a collaboration agreement with Biogen Idec Inc. (BIIB) with a potential value of $299 million to develop and commercialize the drug developer's investigational treatment for spinal muscular atrophy. </p> <p>... Wed, 04 Jan 2012 09:39:20 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ISIS&article=49892456&headline=sanofi-regenerons-anti-cholesterol-drug-has-good-test-results http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ISIS&article=49892456&headline=sanofi-regenerons-anti-cholesterol-drug-has-good-test-results <div class='newsbody'><pre> By Sten Stovall Of DOW JONES NEWSWIRES </pre> <p> LONDON -(Dow Jones)- French drug maker Sanofi SA (SNY) and U.S. biotech Regeneron Pharmaceuticals Inc. (REGN) Thursday said their novel anti-cholesterol drug REGN727 produced positive preliminary results in mid-stage clinical... Thu, 10 Nov 2011 10:21:31 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ISIS&article=46498557&headline=sanofi-deal-brings-risk-opportunity-to-genzyme-partners http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ISIS&article=46498557&headline=sanofi-deal-brings-risk-opportunity-to-genzyme-partners <div class='newsbody'><pre> By Thomas Gryta Of DOW JONES NEWSWIRES </pre> <p> NEW YORK -(Dow Jones)- Following Genzyme Corp's (GENZ) planned takeover by Sanofi-Aventis SA (SNY, SAN.FR), the biotech company leaves several smaller partners in danger of losing a major collaborator, and brings an opportunity... Wed, 16 Feb 2011 15:01:13 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ISIS&article=45990419&headline=isis-ceo-sees-partner-genzyme-being-acquired-by-sanofi-reuters http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ISIS&article=45990419&headline=isis-ceo-sees-partner-genzyme-being-acquired-by-sanofi-reuters <div class='newsbody'><p> DOW JONES NEWSWIRES </p> <p> French drug maker Sanofi-Aventis SA (SNY) will likely succeed in its hostile bid to acquire U.S. biotechnology company Genzyme Corp. (GENZ), the chief executive of Genzyme drug-development partner Isis Pharmaceuticals Inc. (ISIS) told Reuters in... Wed, 12 Jan 2011 11:16:47 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ISIS&article=43880344&headline=isis-genzyme-cholesterol-drug-works-but-safety-concerns-loom http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ISIS&article=43880344&headline=isis-genzyme-cholesterol-drug-works-but-safety-concerns-loom <div class='newsbody'><pre> By Thomas Gryta Of DOW JONES NEWSWIRES </pre> <p> NEW YORK -(Dow Jones)- Isis Pharmaceuticals Inc. (ISIS) and Genzyme Corp. (GENZ) reported the success of two late-stage clinical trials of mipomersen in lowering cholesterol in patients with extremely high levels, but concerns... Wed, 04 Aug 2010 13:26:34 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ISIS&article=43323041&headline=correct-sanofi-aventis-forms-alliance-with-alnylam-isis-venture http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ISIS&article=43323041&headline=correct-sanofi-aventis-forms-alliance-with-alnylam-isis-venture <div class='newsbody'><p> ("Sanofi-Aventis Forms Alliance With Alnylam-Isis Venture" published at 6:29 a.m., EDT, incorrectly stated that the alliance would work on gene-based therapies in the first paragraph. The corrected version follows) </p> <pre> DOW JONES NEWSWIRES </pre> <p> Sanofi-Aventis SA... Tue, 22 Jun 2010 08:35:47 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ISIS&article=43321139&headline=sanofi-aventis-forms-alliance-with-alnylam-isis-venture http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ISIS&article=43321139&headline=sanofi-aventis-forms-alliance-with-alnylam-isis-venture <div class='newsbody'><pre> DOW JONES NEWSWIRES </pre> <p> Sanofi-Aventis SA (SNY, SAN.FR) has entered into an alliance with Regulus Therapeutics Inc. to discover, develop and commercialize gene-based therapies that initially will focus on fibrosis in a deal potentially valued at more than $750 million... Tue, 22 Jun 2010 06:59:22 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ISIS&article=43316444&headline=sanofi-strategic-partnership-with-regulus-therapeutics http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ISIS&article=43316444&headline=sanofi-strategic-partnership-with-regulus-therapeutics <div class='newsbody'><p> PARIS -(Dow Jones)- French pharmaceutical group Sanofi Aventis (SNY) and U.S.-basec company Regulus Inc. Tuesday said they entered into a global strategic alliance to discover, develop, and commercialize microRNA therapeutics. The alliance will initially focus on the therapeutic... Tue, 22 Jun 2010 01:40:49 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ISIS&article=42202540&headline=glaxosmithkline-isis-pharmaceuticals-sign-collaboration-pact http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ISIS&article=42202540&headline=glaxosmithkline-isis-pharmaceuticals-sign-collaboration-pact <div class='newsbody'><p> LONDON -(Dow Jones)- GlaxoSmithKline PLC (GSK), a pharmaceutical company, said Wednesday it has entered into a strategic alliance with Isis Pharmaceuticals Inc. (ISIS) that will apply the Isis antisense drug discovery platform to seek out and develop new therapeutics against... Wed, 31 Mar 2010 06:51:23 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ISIS&article=41477672&headline=isis-genzyme-cholesterol-drug-succeeds-but-concerns-remain http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ISIS&article=41477672&headline=isis-genzyme-cholesterol-drug-succeeds-but-concerns-remain <div class='newsbody'><pre> By Thomas Gryta Of DOW JONES NEWSWIRES </pre> <p> NEW YORK -(Dow Jones)- Genzyme Corp. (GENZ) and Isis Pharmaceuticals Inc. (ISIS) reported the success of a late-stage trial of cholesterol treatment mipomersen, but concerns about the drug's side effects continue to weigh on... Wed, 10 Feb 2010 10:28:39 EST